Abstract:685 Background: mUC often carries a poor prognosis, and a subset of patients (pts) progresses within weeks of starting frontline therapy. While clinicopathologic predictors such as the Bellmunt score have been proposed, predicting this high-risk subset is challenging. Next generation sequencing (NGS) may identify predictive biomarkers for pts with rapid tumor progression, but the predictive value of variant allele frequency (VAF) of genomic alterations is uncertain. Methods: An IRB-approved, HIPAA-compliant single institution retrospective database of pts diagnosed with mUC from 1/2013-3/2023 with somatic NGS and were treated with standard of care therapy was generated. Baseline demographics, clinicopathologic features, and NGS results including pathogenic/likely pathogenic mutations, fusions, copy number alterations, and VAF were extracted from the electronic health record. Progression-free survival (PFS) was calculated from the start of frontline (1L) treatment until radiographic/pathologic progression or death from cancer, whichever came first. PFS 180 days was considered sustained response (SR). Statistical analysis included chi-square and student paired t-test. Results: 260 pts with mUC were identified, and 86 pts had available NGS data. Clinical data cutoff was 9/2023. NGS results used in this analysis were based on the primary tumor (64.0%), distant metastasis (27.9%), or blood (5.8%). Comparing the RP cohort (n=29) vs SR cohort (n=40), there were no significant differences for median age at mUC onset (68 v 68 yrs), proportion of female pts (34 v 28%), Black ancestry (14 v 5%), or smoking history (66 v 68%). Notable variant histologies included squamous cell (28 v 10%, p=0.051) and small cell (0 v 10%, p=NA). 1L treatment involved cisplatin (38 v 43%), carboplatin (17 v 35%), oxaliplatin (0 v 2.5%), or immune checkpoint inhibitor monotherapy (45 v 20%). At mUC, RP cohort pts had more liver metastases (31 v 10%, p=0.027). Median TMB was 10.5 (n=17) vs 6.6 mut/Mb (n=27). No significant difference between RP and SR was observed in the incidence of alterations in TP53 (52 v 58%), TERT promoter (50 v 71%), PIK3CA (41 v 28%), ARID1A (27 v 23%), and KMT2D (14 v 26%). Pts in the RP cohort were significantly more likely to have lower VAF for TP53 ( p=0.006) and KMT2D ( p=0.028). Amongst 1L platinum-treated pts, low TP53 VAF remained significantly associated with the RP cohort ( p=0.010) and KMT2D VAF nearly significant ( p=0.077). Conclusions: Pts with mUC who rapidly progressed on frontline therapy had a significantly higher liver involvement at mUC diagnosis, a trend toward squamous histology, and a significantly lower VAF for TP53 and KMT2D alterations. VAF is a potential predictive biomarker that should be further investigated. We plan to validate these findings in larger cohorts.

Single-center analysis on a real-world cohort of patients with metastatic urothelial carcinoma studied by NGS: Molecular landscape and efficacy of targeted therapies.

Single-center analysis of a real-world cohort of patients with metastatic urothelial carcinoma evaluated by NGS: molecular landscape and efficacy of targeted therapies

Clinicogenomic characterization of patients with rapid tumor progression versus sustained response to frontline systemic therapy for metastatic urothelial carcinoma (mUC).

Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer

Genomic correlates of response and resistance to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

The genomic and transcriptomic landscape of metastastic urothelial cancer

Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients

The evolving treatment landscape of metastatic urothelial cancer

Novel Use of Ctdna to Identify Muscle-Invasive and Non-Organ-confined Upper Tract Urothelial Carcinoma.

Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients

Optimizing the use of next-generation sequencing assays in patients with urothelial carcinoma: recommendations by the 2023 San Raffaele Retreat panel

Real-world treatment patterns and outcomes of patients with unresectable or metastatic urothelial carcinoma receiving systemic therapy in Japan

Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021

Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma

Trends over time in the proportion of sequential treatment and overall survival in patients with metastatic urothelial carcinoma in real-world practice.

Contemporary survival in metastatic bladder cancer patients: A population-based study

Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study

Characterization of Complete Responders to Nivolumab + Gemcitabine-Cisplatin Vs Gemcitabine-Cisplatin Alone and Patients with Lymph Node–only Metastatic Urothelial Carcinoma from the CheckMate 901 Trial.

Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience

Prognostic value of integrated liquid biopsies in patients (pts) with metastatic urothelial cancer (mUC).